A polyelectrolyte complex includes nanofibers. The nanofibers include at least one polycationic component and at least one polyanionic component. The nanofibers have a diameter in a range of 20-100 nm. A process for preparing the complex, a method of using the complex, a kit which includes the complex, and a method of inhibiting loss of blood from a wound site by applying the complex to the wound site are also provided.

This disclosure provides a hydrocolloid having a super absorbent material chemically bonded either directly or indirectly to a peroxide. The peroxide is within the hydrocolloid and the peroxide is in an amount of 0.05% to 2% by weight within the hydrocolloid.

Novel compositions and systems for closure of wounds are disclosed. The compositions provide devices of improved flexibility and elasticity and are readily applied to wound sites or over wound closure devices. The present invention is also directed to a novel platinum catalyst for use in such compositions. The catalyst provides for rapid curing on topical surfaces such as skin and bonds to such surfaces in about 2-5 minutes.

An antiseptic composition for use as bone cement, in particular an antiseptic polymethylmethacrylate bone cement. The composition can be cured and comprises a pharmacologically tolerable salt of a monoperoxy dicarboxylic acid, whereby the salt of the monoperoxy dicarboxylic acid can be dissolved from the composition in the presence of water. Preferably, the salt of the monoperoxy dicarboxylic acid in the composition is used in the form of a powder, whereby the powder has a mean particle size of not more than 250 μm. Preferably, the salt of the monoperoxy dicarboxylic acid, in solution at room temperature, is not degraded within 5 min by the catalase enzyme.

An antiseptic composition for use as bone cement, in particular an antiseptic polymethylmethacrylate bone cement. The composition can be cured and comprises a pharmacologically tolerable salt of a monoperoxy dicarboxylic acid, whereby the salt of the monoperoxy dicarboxylic acid can be dissolved from the composition in the presence of water. Preferably, the salt of the monoperoxy dicarboxylic acid in the composition is used in the form of a powder, whereby the powder has a mean particle size of not more than 250 μm. Preferably, the salt of the monoperoxy dicarboxylic acid, in solution at room temperature, is not degraded within 5 min by the catalase enzyme.

A gel is provided which is the condensation reaction product of the following composition: (i) at least one condensation curable silyl terminated polymer having at least one hydrolysable and/or hydroxyl functional group(s) per molecule; (ii) a cross-linker selected from the group of a silicone, an organic polymer, a silane or a disilane molecule which contains at least two hydrolysable groups per molecule; and (iii) a condensation catalyst selected from the group of titanates, zirconates or tin (II). The molar ratio of hydroxyl and/or hydrolysable groups in polymer (i) to hydrolysable groups from component (ii) is between 0.5:1 and 1:1 using a monosilane cross-linker or 0.75:1 to 3:1 using disilanes, and the molar ratio of M-OR or tin (II) functions to the hydroxyl and/or hydrolysable group(s) in polymer (i) is comprised between 0.01:1 and 0.5:1, where M is titanium or zirconium. The composition, and uses for the gel are also disclosed.

Disclosed is an ostomy device with an adhesive wafer for attachment to a skin surface of a user and a collecting bag for collecting output from a stoma. The collecting bag is connected to the adhesive wafer, and the adhesive wafer has a through-going hole for accommodating the stoma of the user. The adhesive wafer includes a backing layer, a first switchable adhesive composition (11), a second absorbent adhesive composition (12), and a release liner.

A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

A biocompatible adhesive is provided comprising one or more water insoluble compounds of structure (1) wherein B is an oligomer derived from a polyester, polyether, polyalkylene glycol, polysilicone or polycarbonate with a MW<10,000 g/mol, Linker L is a urethane, urea bond, or amide bond; Linker L′ is a urethane or urea bond, A is a chain extender of Mw≤3000 g/mol comprising substituted or unsubstituted alkyl, cycloalkyl and/or aromatic groups, W is a terminal adhesive benzene-1,2-diol derivative or a terminal adhesive benzene-1,2,3-diol derivative, m is 0 or 1; and n is 0, 1, 2, 3 or 4; or a cross-linked polymer formed from said compounds. The compound(s) have a Tg lower than 25° C. The biocompatible adhesive is suitable for use without solvent.

A liquid embolic composition of natural polymers, water, and angiographic contrast agents improves neurovascular interventions, making them more reliable, safe, and affordable. The embolic material is made of a single component activated by blood calcium ion, which triggers coagulation, and that offers superior mechanical stability and does not cause fragmentation in the target vessel. The material retains superior long-term mechanical durability after deployment and provides sufficient visualization under fluoroscopy with iodine-based angiographic contrast compounds or other radiopaque compositions. Described herein are aqueous solutions that enable a high concentration gellan gum (greater than 0.5 wt %) to retain sol state even at the range of body temperature (30-40° C.). This discovery means that it is possible to increase the concentration of gellan gum without losing its inject-ability, yet significantly improve its mechanical stability after delivery.